Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.
A legfontosabb adatok
- Ki végzi
- St. Jude Children's Research Hospital
- Hol
- Memphis (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Leállítva
- Fázis
- 2. fázis
- Résztvevők
- 3 fő vett részt
- Kezdés
- 2023. márc. 14.
- Befejezés
- 2024. máj. 8.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Ruxolitinib
- Mesna
- Anti-thymocyte globulin (ATG)
- Cyclosporine
- Cyclophosphamide
- Fludarabine
- Methotrexate
- Total Body Irradiation (radiation treatment)
- Bone marrow infusion
- Busulfan
- Thiotepa
- A regiszteradat frissítve
- 2025. október 2.
- Miért állt le
- Principal Investigator left institution
Ki vehet részt
- Életkor
- 12 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 20 feltétel megnézéseKevesebb
Ki vehet részt
- Diagnosis:
- Patients with high risk acute lymphoblastic leukemia in first remission. Examples include, but are not limited to, patients with certain leukemic cell cytogenetic findings (e.g. t(9;22) or t(4;11)); delayed response to induction chemotherapy; re-emergence of leukemic blasts by MRD (at any level) in patients previously MRD negative; persistently detectable MRD at lower levels; early T-cell precursor (ETP) ALL
- Patients with acute lymphoblastic leukemia beyond first remission
- Patients with Hodgkin's disease beyond first remission or with refractory disease
- Patients with chronic myelogenous leukemia
- Patients with primary or secondary myelodysplastic syndrome
- Patients with Non-Hodgkin's lymphoma beyond first remission or with refractory disease
- Patients with de novo acute myeloid leukemia in or beyond first remission or with relapsed or refractory disease, or myeloid sarcoma (extra-medullary AML)
- Patients with secondary acute myeloid leukemia
- NK cell lymphoblastic leukemia in any CR
- Biphenotypic, bilineage, or undifferentiated leukemia
- Juvenile Myelomonocytic Leukemia (JMML)
- All patients with prior evidence of CNS leukemia must be treated and be in CNS CR; Patients must have a related or unrelated donor matched at 12 of 12 HLA alleles; Patient must have a Karnofsky/Lansky score of 70 or higher; Patients must be 12 years of age or older; Patients must have a shortening fraction >26% or left ventricular ejection fraction >40%; Patients must have bilirubin less than or equal to 2.5 mg/dL and alanine aminotransferase (ALT) less than or equal to 5 times the upper limit of normal; Patients must have creatinine clearance, or a glomerular filtration rate (GFR), greater than 70 mL/min/1.73m2; Patients must be free of severe infection that upon determination of principal investigator precludes BMT; Patients must have FVC >50% predicted OR, if unable to perform pulmonary function testing, must maintain pulse oximetry oxygen saturation >92% on room air; Female patients of childbearing age must have a negative pregnancy test
Ki nem vehet részt
- Patients who have undergone prior HCT
- Patients who are HIV positive
- Patients positive for Hepatitis B surface antigen (HBsAg)
- Patients positive for Hepatitis C
- Patients with latent tuberculosis with positive TB IFN gamma release assay
- Patients who have a peripheral blood stem cell graft source
- Patients who have a non-permissive mismatch at the DPB1 allele
Helyszínek itt: Egyesült Államok
- St. Jude Children's Research HospitalMemphis, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
The participants are being asked to take part in this clinical trial because the participant have a lymphoid or myeloid based cancer diagnosis that requires a bone marrow transplant.
A teljes eredeti leírásKevesebb
Primary Objectives
To estimate the incidence of severe acute GVHD (saGVHD) using a prophylaxis regimen with no calcineurin inhibitors after day +60 post first allogeneic Human Leukocyte antigen (HLA)-matched sibling or unrelated donor HCT for hematological malignancies.
Secondary objective
Determine the cumulative incidence of relapse, NRM, chronic GVHD, and OS in study participants at one year post-transplant.
Exploratory objectives
* To evaluate the pharmacokinetic/pharmacodynamic (PK/PD) profiles of ruxolitinib, fludarabine, and rATG. * To assess immune reconstitution in study participants within the first year post-HCT.
A vizsgálat csoportja
- Transplant PatientsA vizsgált kezelés
Kezelés: Ruxolitinib, Mesna, Anti-thymocyte globulin (ATG), Cyclosporine, Cyclophosphamide, Fludarabine, Methotrexate, Total Body Irradiation (radiation treatment), Bone marrow infusion, Busulfan és Thiotepa
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies
- A regiszteradat frissítve
- 2025. október 2.